Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review

References

• Tonel G, Conrad C. Interplay between keratinocytes and immune cells-recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol. 2009;41:963–8.
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33:13–23.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.
   PubMed Web of Science ®Google Scholar
• Harden JK, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol. 2006; 31:89–93.
   PubMed Web of Science ®Google Scholar
• Eyrich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365:231–8.
   PubMed Web of Science ®Google Scholar
• Hellström AE, Farkkila M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:563–71.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164:10–22.
   PubMed Web of Science ®Google Scholar
• Wlodarczyk M, Sobolewska A, Wojcik B, et al. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients. World J Gastroenterol. 2014;20:7019–26.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Grittner U, Steingraber A, et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512–20.
   PubMed Web of Science ®Google Scholar
• Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology (Basel).ssss 2009;219:263–7.
   PubMed Web of Science ®Google Scholar
• Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22:1471–7.
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486–91.
   PubMed Web of Science ®Google Scholar
• Yayli S, Irla N, Yawalkar N. Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis. Case Rep Dermatol. 2013;5:332–5.
   PubMedGoogle Scholar
• Ruiz-Villaverde R, Galan-Gutierrez M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr. 2012;103:743–6.
   PubMedGoogle Scholar
• Roe E, Puig L, Corella F, et al. Cutaneous adverse effects of biological therapies for psoriasis. Eur J Dermatol. 2008;18:693–9.
   PubMed Web of Science ®Google Scholar
• Delle Sedie A, Bazzichi L, Bombardieri S, Riente L. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol. 2007;36:403–4.
   PubMed Web of Science ®Google Scholar
• Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol. 2007;21:1272–4.
   PubMed Web of Science ®Google Scholar
• Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3:315–8.
   PubMedGoogle Scholar
• Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30:2506–7.
   PubMed Web of Science ®Google Scholar
• Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003;49:160–1.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73.
   PubMed Web of Science ®Google Scholar
• Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223–46.
   PubMedGoogle Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–93.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–94.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;279 Suppl:S48–S51.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–6.
   PubMed Web of Science ®Google Scholar
• Williams HC, Strachan DP. Psoriasis and eczema are not mutually exclusive diseases. Dermatology (Basel). 1994;189:238–40.
   PubMed Web of Science ®Google Scholar
• Welp K, Gieler U, Stander M, Friederich HC. Concomitant psoriasis vulgaris and atopic dermatitis. A study of 1,065 patients with psoriasis. Hautarzt. 1989;40:496–500.
   PubMed Web of Science ®Google Scholar
• Simpson CR, Anderson WJ, Hemls PJ, et al. Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data. Clin Exp Allergy. 2002;32:37–42.
   PubMed Web of Science ®Google Scholar
• Baurecht H, Hotze M, Brand S, et al. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet. 2015;96:104–20.
   PubMed Web of Science ®Google Scholar
• Giardina E, Sinibaldi C, Chini L, et al. Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. Hum Hered. 2006;61:229–36.
   PubMed Web of Science ®Google Scholar
• Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166:179–88.
   PubMed Web of Science ®Google Scholar
• Leung DY, Boquniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113:651–7.
   PubMed Web of Science ®Google Scholar
• Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol. 2006;19:237–40.
   PubMed Web of Science ®Google Scholar
• Rullan P, Murase J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol. 2009;8:873–6.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Antoni C, Mange B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52:522–6.
   PubMed Web of Science ®Google Scholar
• Buka RL, Resh B, Roberts B, et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53:358–9.
   PubMed Web of Science ®Google Scholar